加味远志散联合茴拉西坦治疗遗忘型轻度认知障碍(痰浊蒙窍证)的临床研究  

Clinical Study of Modified Yuanzhi Powder(加味远志散) Combined with Aniracetam for Amnestic Mild Cognitive Impairment(Orifices Confused by Phlegm-Turbid)

作　　者：李斌[1] 谢沛俊 郭静[1] 曹栀[2] 葛玉霞[3] 文跃强[4] LI Bin;XIE Peijun;GUO Jing;CAO Zhi;GE Yuxia;WEN Yueqiang(Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan,China;Chengdu Fifth People’s Hospital,Chengdu 611130,Sichuan,China;The First People's Hospital of Neijiang,Neijiang 641000,Sichuan,China;Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan,China)

机构地区：[1]成都中医药大学附属医院,四川成都610075 [2]成都市第五人民医院,四川成都611130 [3]内江市第一人民医院,四川内江641000 [4]成都中医药大学,四川成都611137

出　　处：《辽宁中医杂志》2021年第2期111-113,共3页Liaoning Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金青年科学基金(81704024);四川省医学科研课题(Q16020);成都中医药大学“杏林学者”学科人才科研提升计划(QNXZ2019014)。

摘　　要：目的观察加味远志散联合茴拉西坦治疗遗忘型轻度认知障碍(aMCI)(痰浊蒙窍证)的临床疗效。方法采用随机对照的研究方法,将符合诊断标准的60例aMCI患者随机分为观察组(30例)和对照组(30例)。对照组口服茴拉西坦片,观察组在对照组基础上合用加味远志散,两组疗程均为8周。治疗前后对两组患者的简易精神状态量表(MMSE)评分、蒙特利尔认知量表(MoCA)评分、中医证候总积分进行比较。结果 (1)治疗前两组MMSE评分和MoCA评分比较,差异无统计学意义(P>0.05);治疗后观察组MMSE评分和MoCA评分均高于对照组(P<0.05)。(2)治疗前两组中医证候总积分比较,差异无统计学意义(P>0.05);治疗后观察组的中医证候总积分低于对照组(P<0.05)。(3)与对照组比较,治疗组在头重如裹、纳呆脘胀、痰多吐涎、肢体困重和泛恶欲呕方面的症状积分有显著降低(P<0.05)。治疗过程中两组均未发现明显不良反应。结论加味远志散对aMCI(痰浊蒙窍证)患者具有较好疗效,在改善患者认知功能和中医证候方面均具有明显优势,且安全性较高。Objective In order to observe the therapeutic efficacy of Modified Yuanzhi Powder(加味远志散) combined with Aniracetam in treating amnestic mild cognitive impairment(aMCI)(orifices confused by phlegm-turbid).Methods By following a randomized controlled trial design,60 eligible patients were randomized into observation group and control group.The observation group was intervened by Modified Yuanzhi Powder and Aniracetam,while the control group was intervened by Aniracetam only.The intervention of two groups both lasted eight weeks.Before and after treatment,the Mini-Mental State Examination(MMSE),Montreal Cognitive Assessment(MoCA),TCM syndrome and score of two groups were compared.Results There were no significant differences in MMSE score or MoCA score between the two groups before treatment(P>0.05).The two indicators of the observation group were lower than those of the control group after treatment(P<0.05).There was no significant difference in the scores of TCM syndrome between the two groups before treatment(P>0.05).After treatment,the scores of TCM syndrome in the observation group were lower than those in the control group(P<0.05).Compared with those of the control group,the scores of treatment group in TCM syndrome declined,including heaviness of the head,loss of appetite and abdominal distention,excessive phlegm and salivates(P<0.05).No significant adverse reactions were found in the two groups during the treatment.Conclusion Modified Yuanzhi Powder can effectively improve the clinical symptoms,and shows good therapeutic efficacy on TCM syndrome score and safety for patients with aMCI.

关 键 词：遗忘型轻度认知障碍 痰浊蒙窍 加味远志散 临床研究 

分 类 号：R749.16[医药卫生—神经病学与精神病学]